Clinical Trial Update: A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1]) [Phase 1]

View source ↗

Summary

This completed Phase 1 study evaluated the safety, tolerability, and pharmacodynamics of verubecestat (MK-8931) in participants with Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Verubecestat (MK-8931) (verubecestat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED